Lineage Cell Therapeutics FY2024 EPS Raised by Cantor Fitzgerald

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Stock analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for Lineage Cell Therapeutics in a research note issued on Monday, November 18th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will earn ($0.14) per share for the year, up from their prior forecast of ($0.18). The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.11) per share.

Separately, Craig Hallum initiated coverage on shares of Lineage Cell Therapeutics in a report on Tuesday, August 20th. They set a “buy” rating and a $4.00 target price on the stock.

Lineage Cell Therapeutics Stock Down 16.0 %

NYSEAMERICAN LCTX opened at $0.50 on Thursday. The company has a market capitalization of $95.16 million, a PE ratio of -4.20 and a beta of 1.28. Lineage Cell Therapeutics has a one year low of $0.50 and a one year high of $1.61.

Institutional Trading of Lineage Cell Therapeutics

A number of large investors have recently made changes to their positions in LCTX. Raffles Associates LP lifted its stake in Lineage Cell Therapeutics by 35.8% in the second quarter. Raffles Associates LP now owns 4,357,781 shares of the company’s stock worth $4,346,000 after acquiring an additional 1,147,800 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Lineage Cell Therapeutics by 35.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock worth $435,000 after purchasing an additional 114,762 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Lineage Cell Therapeutics by 15.1% during the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after purchasing an additional 17,411 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock worth $239,000 after purchasing an additional 70,418 shares in the last quarter. Finally, Comerica Bank increased its holdings in Lineage Cell Therapeutics by 84,745.8% in the first quarter. Comerica Bank now owns 250,295 shares of the company’s stock valued at $370,000 after buying an additional 250,000 shares during the last quarter. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.